Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain.
Journal
NPJ primary care respiratory medicine
ISSN: 2055-1010
Titre abrégé: NPJ Prim Care Respir Med
Pays: England
ID NLM: 101631999
Informations de publication
Date de publication:
10 03 2022
10 03 2022
Historique:
received:
30
06
2021
accepted:
22
12
2021
entrez:
11
3
2022
pubmed:
12
3
2022
medline:
30
3
2022
Statut:
epublish
Résumé
The aim of this observational, retrospective study was to describe characteristics, treatment patterns, and adherence among patients with asthma who initiated multiple-inhaler triple therapy (MITT) in Catalonia, Spain. This study used data of patients initiating MITT in 2016 from the SIDIAP (Information System for Research in Primary Care) database, which covers ~80% of the Catalonian population (5.8 million). Of 1,204 patients initiating MITT, 361 (30.0%) stepped down (discontinued ≥ 1 and continued ≥1 MITT component) and 89 (7.4%) stopped all three components of MITT for a period of 60 days during the following 12 months. In the follow-up period, 196 (16.3%) patients were considered adherent to MITT (>0.8 proportion of days covered [PDC]), with a mean (standard deviation) PDC of 0.52 (0.51) days. Given the low adherence and substantial rates of step down/discontinuation among patients initiating MITT, there is an urgent need to implement strategies to improve treatment adherence/persistence.
Identifiants
pubmed: 35273167
doi: 10.1038/s41533-022-00270-2
pii: 10.1038/s41533-022-00270-2
pmc: PMC8913688
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Adrenergic beta-2 Receptor Agonists
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11Informations de copyright
© 2022. The Author(s).
Références
Ann Allergy Asthma Immunol. 2005 Dec;95(6):535-40
pubmed: 16400892
J Asthma. 2015;52(10):1073-83
pubmed: 26291137
Breathe (Sheff). 2021 Mar;17(1):200279
pubmed: 34295395
J Asthma. 2019 Mar;56(3):332-340
pubmed: 29624458
Ann Allergy Asthma Immunol. 2019 Jul;123(1):57-63.e2
pubmed: 31028894
Breathe (Sheff). 2019 Mar;15(1):e20-e27
pubmed: 31031841
Respir Res. 2020 Oct 29;21(1):285
pubmed: 33121501
J Allergy Clin Immunol Pract. 2019 Sep - Oct;7(7):2298-2306.e12
pubmed: 30928659
Eur Respir J. 2018 Jan 4;51(1):
pubmed: 29301919
JAMA. 2017 Jan 17;317(3):269-279
pubmed: 28114551
J Asthma. 2018 Feb;55(2):208-219
pubmed: 28586296
J Investig Allergol Clin Immunol. 2011;21(6):466-71
pubmed: 21995180
J Asthma. 2019 Aug;56(8):861-871
pubmed: 30003827
NPJ Prim Care Respir Med. 2021 Mar 22;31(1):16
pubmed: 33753747
Arch Bronconeumol (Engl Ed). 2019 Oct;55(10):509-510
pubmed: 30850192
N Engl J Med. 2012 Sep 27;367(13):1198-207
pubmed: 22938706
World Allergy Organ J. 2010 Mar;3(3):48-52
pubmed: 23282417
Stat Med. 2008 Sep 20;27(21):4238-53
pubmed: 18203120
Med Clin (Barc). 2012 May 19;138(14):617-21
pubmed: 22444996
Int J Chron Obstruct Pulmon Dis. 2020 Jul 10;15:1643-1654
pubmed: 32764910
Curr Med Res Opin. 2020 Jun;36(6):1049-1057
pubmed: 32363945
Lancet Respir Med. 2021 Jan;9(1):69-84
pubmed: 32918892
Lancet. 2019 Nov 9;394(10210):1737-1749
pubmed: 31582314
Lancet Respir Med. 2017 Sep;5(9):691-706
pubmed: 28822787
Lancet Respir Med. 2020 Oct;8(10):1000-1012
pubmed: 32653074
J Allergy Clin Immunol. 2004 Feb;113(2):245-51
pubmed: 14767437
Arch Bronconeumol. 2007 Jan;43(1):29-35
pubmed: 17257561
BMC Public Health. 2012 Mar 19;12:204
pubmed: 22429515
Arch Bronconeumol (Engl Ed). 2021 Mar;57(3):205-213
pubmed: 33004238
Respir Med. 2005 Oct;99(10):1263-7
pubmed: 16140227
Respir Investig. 2021 Jul;59(4):454-463
pubmed: 33741320
Arch Bronconeumol. 2009 Oct;45(10):481-6
pubmed: 19525051
J Allergy Clin Immunol Pract. 2020 Jun;8(6):1961-1969.e6
pubmed: 31857262